LONDON/KISUMU, Kenya (Archyde.com) – After decades of work, the World Health Organization approved the first-ever malaria vaccine last year – a historic step that promised to roll back a child-killing disease every minute.
In reality, efforts fall far short of that, with a lack of funding and market potential hampering GSK Plc’s ability to produce as many doses of its vaccine as needed, according to Archyde.com interviews with a dozen senior officials. WHO, GSK staff, scientists and non-profit groups.
The British drugmaker has pledged to produce up to 15 million doses every year until 2028, following pilot programs in 2019 – considerably less than the WHO says is needed. He is currently unlikely to earn more than a few million a year before 2026, according to a source familiar with the rollout of the vaccine.
A GSK spokesman told Archyde.com it might not manufacture enough of its Mosquirix vaccine to meet the vast demand without more funds from international donors, without giving details on how many doses it planned to make. produce each year during the first years of deployment.
“Demand over the next five to 10 years is likely to exceed current supply forecasts,” said Thomas Breuer, GSK’s director of global health. … continuation of the article on Other press